At JRG Partners we sit on the other side of these searches every day, so this reflects what we actually see working for candidates. Clinical research professionals hold expertise that pharmaceutical companies genuinely need at senior levels, but the move into executive leadership requires building commercial, financial, and organisational capability that clinical careers do not develop. The people who make this transition successfully treat it as acquiring a second discipline rather than as recognition of their existing one.
Key Takeaways
- Clinical expertise is valuable but not sufficient for executive roles.
- Development strategy sits between clinical work and executive leadership.
- Commercial and financial literacy must be built deliberately.
- Cross-functional programme leadership is the usual bridge.
- Expect to be a learner in areas where others have deep expertise.
What Clinical Careers Build and What They Do Not
Clinical research develops rigorous scientific reasoning, understanding of evidence generation, regulatory awareness, and often substantial project management capability. What it does not typically develop is commercial understanding of how products compete and are reimbursed, financial literacy about capital allocation and valuation, or experience leading organisations with functions outside your expertise. Executive roles demand these, and recognising the gap honestly is the starting point for a transition that many clinical professionals attempt without adequate preparation.
Development Strategy as the Natural Step
The most natural progression runs through development strategy: roles that require deciding what studies to run, how programmes should be sequenced, how evidence needs balance against time and cost, and how development choices affect commercial outcomes. These roles use clinical expertise while demanding the tradeoff judgment executive work requires, and they expose you to regulatory strategy, commercial input, and capital considerations. Seeking programme or asset leadership rather than deepening functional clinical operations expertise is usually the higher-return move.
Build Commercial and Financial Literacy Deliberately
Commercial and financial understanding will not accumulate incidentally, so it must be pursued: spending time with commercial and market access colleagues, understanding how forecasts are built and what drives them, learning how the company is valued and what investors weigh, and understanding the economics of the decisions your programmes imply. Clinical professionals who can discuss the commercial implications of a development choice, rather than only its scientific merit, are perceived quite differently in leadership conversations, and the shift is achievable with deliberate effort.
Accepting the Learner Position
Clinical professionals frequently hold significant expertise and authority in their domain, and entering discussions where commercial or financial colleagues know substantially more can be uncomfortable. The response matters: those who engage as genuine learners build the breadth executive roles require, while those who retreat to clinical authority or dismiss commercial reasoning as less rigorous tend to remain in functional roles. This is a predictable dynamic and much easier to navigate when anticipated.
What This Looks Like in Practice
A clinical research professional seeking executive leadership pursues development or asset leadership roles that demand tradeoff judgment, deliberately builds commercial and financial literacy through time with those functions, learns how the company is valued and forecasts are built, and engages as a learner where colleagues hold deeper expertise.
The Mistake Candidates Keep Making
The most common mistake is deepening clinical operations or medical expertise on the assumption that greater domain authority leads to executive roles. It generally leads to more senior functional roles, which is a legitimate destination but a different one. The professional mistakes depth for breadth and finds that executive candidacy requires capabilities they have not built.
Building the Bridge From Clinical to Executive
| Step | What It Develops |
|---|---|
| Development or asset leadership | Tradeoff judgment across functions |
| Time with commercial and access | Understanding of competitive reality |
| Forecasting and valuation literacy | Financial reasoning executives use |
| Cross-functional programme roles | Leading beyond your own expertise |
| Board or investor exposure | How the company is judged externally |
The Bottom Line
Moving from clinical research into executive leadership means acquiring commercial, financial, and organisational capability rather than deepening clinical authority, so pursue development and asset leadership roles that demand tradeoff judgment and build the adjacent literacy deliberately. None of this is quick, but it compounds, and the candidates who start early are the ones with options later.
Related Reading
For more, see Career Advancement Tips for Pharmaceutical Sales Leaders, Resume Strategies for Pharma Regulatory Affairs Professionals, How to Recruit a Chief Medical Officer for a Pharma Company.
Frequently Asked Questions
- Q: What does clinical research not prepare you for?
- A: Commercial understanding of competition and reimbursement, financial literacy about capital allocation and valuation, and leading organisations with functions outside your own expertise.
- Q: What is the natural next step?
- A: Development or asset leadership roles that require deciding what studies to run and how evidence needs balance against time, cost, and commercial outcomes.
- Q: How do I build commercial literacy?
- A: Deliberately, through time with commercial and market access colleagues, understanding forecasting, and learning how the company is valued and what investors weigh.
- Q: Why does deepening clinical expertise not lead to executive roles?
- A: Because it produces more senior functional roles, a legitimate but different destination, while executive candidacy requires breadth the clinical track does not build.
- Q: What is the hardest part of the transition?
- A: Accepting the learner position in commercial and financial discussions after holding substantial authority in a clinical domain, which determines whether breadth develops.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
